258 / 330
258
28
TH
CONGRESS OF THE ESPU
MATERIAL AND METHODS
Patients with spina bifida who underwent urodynamic study before and after the use of Mirabegron
were included in this retrospective analysis.
RESULTS
Total 39(27 male and 12 female) patients met the criteria and were included. Meningomyelocele,
lipomeningomyelocele and sacral agenesis had been diagnosed in 11, 26, and 2 patients,
respectively. Mirabegron was started at median 12.3 years. Pre-Mirabegron urodynamic study
(preUDS) was performed at median 12.1 years. All of them were on anticholinergic medication
before Mirabegron treatment. PreUDS was performed after washout period of anticholinergics in
24 patients (group 1). In the other 15 patients, it was performed during anticholinergic medication
(group 2). After 8-12 weeks of Mirabegron (50mg) alone therapy, urodynamic study was performed
again at median 12.6 years.
In group 1, median maximal cystometric capacity was increased from 244.5 to 353.5ml (p=0.002).
Median compliance was increased from 11.4 to 24.0ml/cmH2O (p=0.007). Involuntary contrac-
tion was observed in 9 (37.5%) and 6 (25.0%) patients before and after Mirabegron, respectively
(p=0.534).
In group 2, median maximal cystometric capacity was 211.0 before Mirabegon and 261.0ml
after Mirabegron (p=0.089). Median compliance was 14.8 and 20.8ml/cmH2O (p=0.087), respec-
tively. Involuntary contraction was observed in 3 (20.0%) and 5 (33.3%) patients before and after
Mirabegron, respectively (p=0.385).
Among 39 total patients, vesicoureteral reflux was observed in 11 renal units in 7 patients before
Mirabegron and 5 renal units in 5 patients after Mirabegron.
CONCLUSIONS
Mirabegron showed urodymic efficacy regarding maximal cystometry capacity and compliance in
pediatric patients with spina bifida. Although it showed better MCC and compliance when compared
with anticholinergics, it was not statistically significant. Large, multi-center prospective study should
be followed.
12:04–12:16
Discussion
12:16–12:19
S24-5 (PP)
MIRABEGRON IN TREATMENT
OF PATIENTS WITH NEUROGENIC BLADDER RESISTANT
TO ANTICHOLINERGIC THERAPY
Lidia SKOBEJKO-WLODARSKA, Gabriela GROCHOWSKA
and Malgorzata BAKA-OSTROWSKA
Children’s Memorial Health Institute, Paediatric Urology, Warsaw, POLAND
PURPOSE
Evaluation of mirabegron efficacy in treatment patients with neurogenic bladder resistant to anticho-
linergic therapy